MPRrokote

MPRrokote is the Finnish name for the measles, mumps, and rubella vaccine. It is a combined vaccine that provides immunity against these three viral diseases. In Finland, MPRrokote is part of the routine childhood immunization program, typically administered in two doses. The first dose is usually given between 12 and 18 months of age, and the second dose is administered between four and six years of age.

The vaccine is a live attenuated virus vaccine, meaning it contains weakened versions of the measles, mumps, and rubella viruses. These weakened viruses stimulate the immune system to produce antibodies and memory cells, which protect against future infections by the actual diseases. The effectiveness of the MMR vaccine is very high, with two doses providing lifelong protection for most individuals.

Like all vaccines, MPRrokote can cause side effects, though they are generally mild and temporary. Common side effects include fever, a mild rash, or pain and redness at the injection site. Serious side effects are very rare. The vaccine has been extensively studied and is considered safe and effective by public health authorities worldwide, including the Finnish Institute for Health and Welfare (THL). Vaccination with MPRrokote is a crucial public health measure to prevent outbreaks of measles, mumps, and rubella, which can have serious complications.